trending Market Intelligence /marketintelligence/en/news-insights/trending/ye9UOWkogrHln2kDLTYfxQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Abbott's board approves $3B stock buyback

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Abbott's board approves $3B stock buyback

The board of Abbott Laboratories has approved a buyback for up to $3 billion worth of outstanding common shares.

The latest repurchase is in addition to an unused $795 million buyback program that was issued by the Abbott Park, Ill.-based medical-device maker's board in September 2014.

Abbott, which manufactures cardiovascular, diabetes and other devices, recently received U.S. Food and Drug Administration approval for the Architect Stat High Sensitivity Troponin-I blood test. The device helps detect a heart attack faster.